MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Search

Harvard Bioscience Inc

Отворен

СекторЗдравеопазване

0.45

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.44

Максимум

0.46

Ключови измерители

By Trading Economics

Приходи

48M

-2.3M

Продажби

-1.3M

20M

Марж на печалбата

-11.159

Служители

330

EBITDA

40M

155K

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+344.44% upside

Дивиденти

By Dow Jones

Следващи печалби

6.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

347K

20M

Предишно отваряне

0.45

Предишно затваряне

0.45

Настроения в новините

By Acuity

50%

50%

149 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Harvard Bioscience Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.10.2025 г., 23:30 ч. UTC

Горещи акции

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2.10.2025 г., 21:21 ч. UTC

Печалби

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3.10.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2.10.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2.10.2025 г., 23:39 ч. UTC

Пазарно говорене

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2.10.2025 г., 23:00 ч. UTC

Пазарно говорене

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2.10.2025 г., 22:54 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Scales's JV Buyout Lauded by Bull -- Market Talk

2.10.2025 г., 22:54 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Global Forex and Fixed Income Roundup: Market Talk

2.10.2025 г., 22:46 ч. UTC

Пазарно говорене

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2.10.2025 г., 22:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.10.2025 г., 21:17 ч. UTC

Придобивния, сливания и поглъщания

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Energy & Utilities Roundup: Market Talk

2.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.10.2025 г., 20:49 ч. UTC

Придобивния, сливания и поглъщания

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2.10.2025 г., 20:00 ч. UTC

Придобивния, сливания и поглъщания

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2.10.2025 г., 19:20 ч. UTC

Пазарно говорене

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2.10.2025 г., 19:10 ч. UTC

Пазарно говорене

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2.10.2025 г., 19:04 ч. UTC

Пазарно говорене

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2.10.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Сравнение с други в отрасъла

Ценова промяна

Harvard Bioscience Inc Прогноза

Ценова цел

By TipRanks

344.44% нагоре

12-месечна прогноза

Среден 2 USD  344.44%

Висок 2 USD

Нисък 2 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Harvard Bioscience Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

1

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

0.3 / 0.3401Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

No Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

149 / 371 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat